PNAS:蛋白RBM38和p53互作调控肿瘤发展

2014-12-31 佚名 不详

科学家早就知道p53蛋白会抑制肿瘤。然而,加州大学戴维斯分校研究人员最近的一项动物研究发现p53与另一种蛋白质RBM38之间有复杂关系,揭示身体如何校准p53蛋白水平。RBM38太多会降低p53水平,增加患癌症的风险。RBM38太少允许p53表达增加,从而导致早衰。这项研究结果发表在PNAS杂志上。 p53蛋白是必要的抑制肿瘤因子,加州大学戴维斯分校教授Xinbin Chen说:当RBM38

科学家早就知道p53蛋白会抑制肿瘤。然而,加州大学戴维斯分校研究人员最近的一项动物研究发现p53与另一种蛋白质RBM38之间有复杂关系,揭示身体如何校准p53蛋白水平。RBM38太多会降低p53水平,增加患癌症的风险。RBM38太少允许p53表达增加,从而导致早衰。这项研究结果发表在PNAS杂志上。

p53蛋白是必要的抑制肿瘤因子,加州大学戴维斯分校教授Xinbin Chen说:当RBM38抑制p53基因,生物体发展肿瘤。敲除RBM38会增加p53,我们认为这可能是一件好事,但太多的p53会抑制细胞周期进程,导致细胞死亡,早衰甚至癌症。

p53和RBM38之间的关系可以被描述为一个循环:p53调节RBM38表达,而RBM38抑制p53蛋白。有时候,结果是不可预知的,甚至是相互矛盾的。高RBM38水平已经在某些乳腺癌和大肠癌中被发现。然而,RBM38增加也与胶质母细胞瘤、卵巢癌和其他形式的乳腺癌预后较好有关。

考虑到RBM38在癌症中扮演复杂的角色,Chen和他的团队想了解是否RBM38删除会发生什么。是否会增加p53水平提高肿瘤抑制?

答案是没有,剔除RBM38会增加p53基因,引起血液形成出现问题,增加对电离辐射敏感性和过早老化。我们发现,剔除RBM38小鼠有伤口愈合问题,贫血等衰老表现,增加p53水平会导致细胞凋亡,从而导致寿命较短。

也许最令人惊讶的是,动物也增加了患癌症风险。RBM38的缺失会影响一些与癌症相关的炎性基因。这在p53基因缺失小鼠以及那些p53功能缺失的小鼠中特别明显。RBM38和p53之间的相互调节对老化和肿瘤发生非常重要,这是可能的,针对RBM38使肿瘤细胞中p53水平升高,这可能会杀死肿瘤细胞,抑制癌症的发展

原始出处:

Zhang J, Xu E, Ren C, Yan W, Zhang M, Chen M, Cardiff RD, Imai DM, Wisner E, Chen X.Mice deficient in Rbm38, a target of the p53 family, are susceptible to accelerated aging and spontaneous tumors.Proc Natl Acad Sci U S A. 2014 Dec 15. pii: 201415607.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1797904, encodeId=881c1e97904c5, content=<a href='/topic/show?id=bbd62410e51' target=_blank style='color:#2F92EE;'>#互作调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24107, encryptionId=bbd62410e51, topicName=互作调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Tue Jul 14 10:28:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969120, encodeId=817a1969120e9, content=<a href='/topic/show?id=44b482858c1' target=_blank style='color:#2F92EE;'>#肿瘤发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82858, encryptionId=44b482858c1, topicName=肿瘤发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Mon Nov 02 10:28:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855681, encodeId=703b1855681e3, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Jun 06 22:28:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372358, encodeId=18d913e2358c0, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Jan 02 00:28:00 CST 2015, time=2015-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471504, encodeId=4ebf14e150423, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri Jan 02 00:28:00 CST 2015, time=2015-01-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1797904, encodeId=881c1e97904c5, content=<a href='/topic/show?id=bbd62410e51' target=_blank style='color:#2F92EE;'>#互作调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24107, encryptionId=bbd62410e51, topicName=互作调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Tue Jul 14 10:28:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969120, encodeId=817a1969120e9, content=<a href='/topic/show?id=44b482858c1' target=_blank style='color:#2F92EE;'>#肿瘤发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82858, encryptionId=44b482858c1, topicName=肿瘤发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Mon Nov 02 10:28:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855681, encodeId=703b1855681e3, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Jun 06 22:28:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372358, encodeId=18d913e2358c0, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Jan 02 00:28:00 CST 2015, time=2015-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471504, encodeId=4ebf14e150423, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri Jan 02 00:28:00 CST 2015, time=2015-01-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1797904, encodeId=881c1e97904c5, content=<a href='/topic/show?id=bbd62410e51' target=_blank style='color:#2F92EE;'>#互作调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24107, encryptionId=bbd62410e51, topicName=互作调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Tue Jul 14 10:28:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969120, encodeId=817a1969120e9, content=<a href='/topic/show?id=44b482858c1' target=_blank style='color:#2F92EE;'>#肿瘤发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82858, encryptionId=44b482858c1, topicName=肿瘤发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Mon Nov 02 10:28:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855681, encodeId=703b1855681e3, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Jun 06 22:28:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372358, encodeId=18d913e2358c0, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Jan 02 00:28:00 CST 2015, time=2015-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471504, encodeId=4ebf14e150423, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri Jan 02 00:28:00 CST 2015, time=2015-01-02, status=1, ipAttribution=)]
    2015-06-06 drwjr
  4. [GetPortalCommentsPageByObjectIdResponse(id=1797904, encodeId=881c1e97904c5, content=<a href='/topic/show?id=bbd62410e51' target=_blank style='color:#2F92EE;'>#互作调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24107, encryptionId=bbd62410e51, topicName=互作调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Tue Jul 14 10:28:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969120, encodeId=817a1969120e9, content=<a href='/topic/show?id=44b482858c1' target=_blank style='color:#2F92EE;'>#肿瘤发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82858, encryptionId=44b482858c1, topicName=肿瘤发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Mon Nov 02 10:28:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855681, encodeId=703b1855681e3, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Jun 06 22:28:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372358, encodeId=18d913e2358c0, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Jan 02 00:28:00 CST 2015, time=2015-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471504, encodeId=4ebf14e150423, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri Jan 02 00:28:00 CST 2015, time=2015-01-02, status=1, ipAttribution=)]
    2015-01-02 zhishijing
  5. [GetPortalCommentsPageByObjectIdResponse(id=1797904, encodeId=881c1e97904c5, content=<a href='/topic/show?id=bbd62410e51' target=_blank style='color:#2F92EE;'>#互作调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24107, encryptionId=bbd62410e51, topicName=互作调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Tue Jul 14 10:28:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969120, encodeId=817a1969120e9, content=<a href='/topic/show?id=44b482858c1' target=_blank style='color:#2F92EE;'>#肿瘤发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82858, encryptionId=44b482858c1, topicName=肿瘤发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Mon Nov 02 10:28:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855681, encodeId=703b1855681e3, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Jun 06 22:28:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372358, encodeId=18d913e2358c0, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Jan 02 00:28:00 CST 2015, time=2015-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471504, encodeId=4ebf14e150423, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri Jan 02 00:28:00 CST 2015, time=2015-01-02, status=1, ipAttribution=)]
    2015-01-02 ylz8405

相关资讯

PNAS:“基因守护者”p53蛋白的突变体助长癌症扩散

近日,研究者最新发现关于体内一种重要的肿瘤抑制蛋白p53的新功能,这个蛋白曾被称为“基因守护者”。当由于压力的因素致使健康细胞DNA损伤时,这种蛋白就会首先出来保护DNA,例如当机体暴露在有毒化学物质或强烈的太阳紫外线下时,如果损伤非常严重,p53就会启动细胞死亡或细胞凋亡预编程序。然而p53的突变体不再履行生命机能的作用,也就是说,它变成了大量不同种类癌症的推动者。[pdf fr

Plos One:抑癌基因p53降低肝癌上皮间质转化,抑制转移

中科院上海生命科学研究院营养科学所陈雁研究组在一项最新研究中,揭示了抑癌基因p53在肝癌细胞由上皮间质转化(EMT)以及肝癌转移中发挥的重要作用。近日,相关研究论文在线发表于Plos One。 肝细胞癌是癌症致死率最高的三大恶性肿瘤之一,其高度转移的特性成为临床治疗的最大障碍。肝癌病人的癌组织中常见p53基因的突变,尽管p53在肿瘤起始及发展中的生理功能已经得到详尽的

Oncogene:时玉舫等发现间充质干细胞中p53缺失对肿瘤发生的作用

近日,国际学术期刊Oncogene 在线发表了中国科学院上海生命科学研究院健康科学研究所时玉舫研究组题为p53 Regulates Mesenchymal Stem Cell-mediated Tumor Suppression in a Tumor Microenvironment through Immune Modulation 的研究论文,报道了抑癌基因p53缺失在间充质干细胞(Mesen

Cell Reports:p53与ARF突变癌症患者可受益于JAM抑制剂

最近一项新研究证实,一些侵略性癌症患者可从一类用于治疗类风湿关节炎的抗炎药中受益。通过研究三阴性乳腺癌,华盛顿大学医学院研究人员发现一些侵略性肿瘤依赖于一种驱动炎症的抗病毒途径。 这个特殊抗病毒途径激活的肿瘤总是有不正常形式的p53与ARF蛋白,p53与ARF蛋白是由高度变异的两个基因(p53与ARF)编码。研究人员发现两个基因能相互“补偿”。如果两者都发生突变,形成的肿瘤比只有一个基因突变形成

PNAS:日本发现抑制糖尿病蛋白

日本京都府立医科大学11日发表的最新研究结果显示,一种名为p53的蛋白与糖尿病相关,抑制这种蛋白的功能可以改善实验鼠胰岛素分泌和糖耐受水平。研究人员称,这一发现有助于开发治疗糖尿病的新药。 日本研究人员在最新一期美国《国家科学院学报》网络版上报告说,对患有糖尿病的实验鼠研究发现,p53蛋白能与一种名为Parkin的蛋白质结合,导致胰岛β细胞中负责细胞能量代谢的线粒体无法更新、功能下降,使

Nature:揭示“癌症之王”胰腺癌的抑制开关

日前,来自英国比森癌症研究所(Beatson Institute for Cancer Research)的研究人员发现,肿瘤抑制蛋白 p53 蛋白的状态决定了抑制细胞自噬信号通路是促进或是抑制小鼠体内的胰腺癌。这一研究发现为临床自噬抑制剂试验提供了一个警示故事。自噬是细胞吞噬自身,降解和回收细胞质蛋白及细胞器的一个基本过程。这一信号通路在响应各种形式压力促进细胞内稳态